Balance Sheet Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2024-09-13 EDT			5-day change	1st Jan Change
915.50 ^DKK	+1.61%		+10.57%	+145.31%

09-09	Zealand Pharma's Weight Management Drug Shows Positive Topline Results in Early-stage Trial	MT
09-09	Zealand Pharma Weight Loss Treatment Trial Shows up to 8.3% Reduction in Body Weight	MT

866746fd934206f1d7.kX1tTrNyP7jH5YGpgJm5dvScsA-HVSmFVqqnJuhGPzI.qSQsF9U_d9estbna4d3yQcf70SKxZ3CxFMjjUYAMS1jVJVp98koG0fOI0A

Published financial data: ZEALAND PHARMA A/S

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2019	2020	2021	2022	2023
Revenues	41.33M	353M	293M	104M	343M
Total Revenues	41.33M	353M	293M	104M	343M
Cost of Goods Sold, Total	415K	90.56M	119M	-	688M
Gross Profit	40.92M	263M	174M	104M	-345M
Selling General & Admin Expenses, Total	67.88M	468M	636M	270M	216M
Stock-Based Compensation (IS)	-	-	-	-11.24M	-
R&D Expenses	561M	604M	588M	612M	-
Other Operating Expenses	-444K	-602K	-759K	48.27M	-
Other Operating Expenses, Total	629M	1.07B	1.22B	918M	216M
Operating Income	-588M	-809M	-1.05B	-814M	-561M
Interest Expense, Total	-3.2M	-2.9M	-4.09M	-57.79M	-25.83M
Interest And Investment Income	6.29M	1.09M	44K	6.54M	45.32M
Net Interest Expenses	3.09M	-1.81M	-4.05M	-51.25M	19.49M
Currency Exchange Gains (Loss)	5.52M	-39.49M	39.32M	25.6M	-9.71M
Other Non Operating Income (Expenses)	-185K	-4.83M	-3.47M	11.01M	-1.99M
EBT, Excl. Unusual Items	-580M	-855M	-1.02B	-829M	-553M
Restructuring Charges	-	-	-	-19.1M	-
Merger & Related Restructuring Charges	-	-7.1M	-	-	-
Gain (Loss) On Sale Of Investments	2.85M	-1.17M	-6.36M	2.34M	-8.84M
Gain (Loss) On Sale Of Assets	-	-	-	-	-
Asset Writedown	-	-12.74M	-2.17M	-3.99M	-11M
Other Unusual Items	-	36.4M	-	-123M	-136M
EBT, Incl. Unusual Items	-577M	-840M	-1.03B	-972M	-709M
Income Tax Expense	-5.14M	7.08M	-8.79M	-6.43M	-5.13M
Earnings From Continuing Operations	-572M	-847M	-1.02B	-966M	-704M
Earnings Of Discontinued Operations	-	-	-	-237M	-
Net Income to Company	-572M	-847M	-1.02B	-1.2B	-704M
Net Income - (IS)	-572M	-847M	-1.02B	-1.2B	-704M
Net Income to Common Incl Extra Items	-572M	-847M	-1.02B	-1.2B	-704M
Net Income to Common Excl. Extra Items	-572M	-847M	-1.02B	-966M	-704M
Per Share Items
Net EPS - Basic	-16.91	-22.07	-23.75	-26.02	-12.44
Basic EPS - Continuing Operations	-16.91	-22.07	-23.75	-20.9	-12.44
Basic Weighted Average Shares Outstanding	33.8M	38.37M	42.87M	46.2M	56.59M
Net EPS - Diluted	-16.91	-22.07	-23.75	-26.02	-12.44
Diluted EPS - Continuing Operations	-16.91	-22.07	-23.75	-20.9	-12.44
Diluted Weighted Average Shares Outstanding	33.8M	38.37M	42.87M	46.2M	56.59M
Normalized Basic EPS	-10.72	-13.93	-14.85	-11.21	-6.11
Normalized Diluted EPS	-10.72	-13.93	-14.85	-11.21	-6.11
American Depositary Receipts Ratio (ADR)	1	1	1	1	1
Supplemental Items
EBITDA	-583M	-792M	-1.02B	-727M	-555M
EBITA	-588M	-802M	-1.04B	-814M	-561M
EBIT	-588M	-809M	-1.05B	-814M	-561M
EBITDAR	-	-	-	-	-
Effective Tax Rate - (Ratio)	0.89	-0.84	0.86	0.66	0.72
Normalized Net Income	-362M	-534M	-637M	-518M	-346M
Interest on Long-Term Debt	3.39M	7.72M	7.56M	57.79M	28.98M
Supplemental Operating Expense Items
Selling and Marketing Expenses	-	273M	375M	32.3M	30.63M
General and Administrative Expenses	67.88M	196M	261M	237M	185M
Research And Development Expense From Footnotes	561M	604M	588M	614M	685M
Net Rental Expense, Total	-	-	-	-	-
Imputed Operating Lease Interest Expense	-	-	-	-	-
Imputed Operating Lease Depreciation	-	-	-	-	-
Stock-Based Comp., COGS (Total)	-	-	521K	-	29.76M
Stock-Based Comp., R&D Exp. (Total)	12.19M	14M	22.16M	33.84M	-
Stock-Based Comp., S&M Exp. (Total)	-	6.04M	2.26M	649K	1.73M
Stock-Based Comp., G&A Exp. (Total)	2.57M	10.44M	27.97M	31.7M	29.94M
Stock-Based Comp., Other (Total)	-	-	-	-11.24M	-
Total Stock-Based Compensation	14.76M	30.48M	52.91M	54.94M	61.43M

Fiscal Period: December	2019	2020	2021	2022	2023
Assets
Cash And Equivalents	1.08B	960M	1.13B	1.07B	449M
Short Term Investments	299M	297M	-	-	-
Trading Asset Securities, Total	-	-	299M	109M	1.18B
Total Cash And Short Term Investments	1.38B	1.26B	1.43B	1.18B	1.63B
Accounts Receivable, Total	751K	46.48M	73.02M	116M	122M
Other Receivables	15.04M	15.44M	37.36M	21.6M	16.44M
Total Receivables	15.79M	61.93M	110M	137M	139M
Inventory	-	65.04M	118M	1.29M	7.94M
Prepaid Expenses	30.76M	35.16M	64.63M	-	-
Restricted Cash	-	-	-	-	-
Total Current Assets	1.43B	1.42B	1.72B	1.32B	1.78B
Gross Property Plant And Equipment	192M	138M	290M	237M	220M
Accumulated Depreciation	-66.54M	-53.26M	-68.89M	-71.36M	-70.43M
Net Property Plant And Equipment	125M	213M	221M	165M	150M
Long-term Investments	35.63M	32.33M	26.91M	37.84M	21.38M
Other Intangibles, Total	2.48M	57.48M	53.79M	-	12.26M
Accounts Receivable Long-Term	-	-	-	18.1M	15.79M
Deferred Tax Assets Long-Term	-	8.37M	13.52M	2.02M	925K
Other Long-Term Assets, Total	9.01M	31.04M	30.36M	-	-
Total Assets	1.6B	1.76B	2.07B	1.54B	1.98B
Liabilities
Accounts Payable, Total	57.53M	70.38M	64.56M	181M	91.61M
Accrued Expenses, Total	43.1M	36.43M	28.7M	-	85.2M
Current Portion of Long-Term Debt	-	-	-	-	-
Current Portion of Leases	7.69M	14.07M	14.9M	14.73M	16.66M
Current Income Taxes Payable	614K	30.39M	-	-	-
Unearned Revenue Current, Total	56.25M	53.18M	53.03M	-	-
Other Current Liabilities	29.95M	151M	173M	-	91.12M
Total Current Liabilities	195M	355M	334M	195M	285M
Long-Term Debt	-	-	648M	401M	-
Long-Term Leases	78.07M	116M	125M	108M	103M
Unearned Revenue Non Current	83.64M	44.59M	14.55M	-	-
Other Non Current Liabilities	-	16.74M	18.43M	19.06M	-
Total Liabilities	357M	533M	1.14B	724M	387M
Common Stock, Total	36.06M	39.8M	43.63M	51.7M	58.75M
Additional Paid In Capital	2.65B	3.47B	4.25B	-	6.41B
Retained Earnings	-1.44B	-2.29B	-3.31B	-	-4.89B
Treasury Stock	-	-	-71.89M	-	-
Comprehensive Income and Other	-	8.98M	14.16M	764M	22.7M
Total Common Equity	1.24B	1.23B	928M	816M	1.59B
Total Equity	1.24B	1.23B	928M	816M	1.59B
Total Liabilities And Equity	1.6B	1.76B	2.07B	1.54B	1.98B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	35.99M	39.55M	43.22M	51.47M	58.38M
ECS Total Common Shares Outstanding	35.99M	39.74M	43.22M	51.47M	58.38M
Book Value / Share	34.53	30.94	21.47	15.85	27.28
Tangible Book Value	1.24B	1.17B	874M	816M	1.58B
Tangible Book Value Per Share	34.46	29.49	20.22	15.85	27.07
Total Debt	85.76M	130M	787M	524M	119M
Net Debt	-1.29B	-1.13B	-641M	-654M	-1.51B
Debt Equivalent Oper. Leases	-	-	-	-	-
Account Code - Inventory Valuation	3	3	5	5	5
Inventories - Raw Materials, Total	-	14.4M	35.82M	1.29M	7.94M
Inventories - Work In Process, Total	-	13.72M	29.59M	-	-
Inventories - Finished Goods, Total	-	36.92M	53.03M	-	-
Buildings, Total	-	34.1M	36.6M	-	-
Machinery, Total	69.65M	101M	107M	82.82M	78.57M
Full Time Employees	179	329	355	196	253

Fiscal Period: December	2019	2020	2021	2022	2023
Net Income	-572M	-847M	-1.02B	-1.2B	-704M
Depreciation & Amortization - CF	13.68M	23.1M	32.39M	102M	20.12M
Amortization of Goodwill and Intangible Assets - (CF)	-	6.86M	7.86M	-	-
Depreciation & Amortization, Total	13.68M	29.96M	40.25M	102M	20.12M
Amortization of Deferred Charges, Total - (CF)	-	-	-	1.34M	1.2M
(Gain) Loss From Sale Of Asset	-	-	2.7M	-	-
Asset Writedown & Restructuring Costs	-	12.74M	6.52M	-1.06M	4.71M
Stock-Based Compensation (CF)	14.76M	30.48M	53.5M	52.58M	61.43M
Net Cash From Discontinued Operations	-	-	-	13.5M	-
Other Operating Activities, Total	123M	-12.98M	-130M	81.38M	139M
Change In Accounts Receivable	-21.06M	-7.72M	-64.49M	18.22M	-6.76M
Change In Inventories	-	-14.4M	-52.77M	50.69M	9.34M
Change In Accounts Payable	17.06M	120M	-49.06M	-58.65M	39.84M
Change in Other Net Operating Assets	14.87M	-	-	-	9.68M
Cash from Operations	-409M	-689M	-1.21B	-942M	-426M
Capital Expenditure	-21.04M	-25.04M	-22.13M	-11.71M	-11.24M
Sale of Property, Plant, and Equipment	25K	-	-	-	-
Cash Acquisitions	-	-168M	-	-	-
Sale (Purchase) of Intangible assets	-2.48M	-	-	-	-12.51M
Investment in Marketable and Equity Securities, Total	-22.8M	-	-	187M	-1.07B
Other Investing Activities, Total	-5.37M	-3.97M	4.01M	106M	-
Cash from Investing	-51.67M	-197M	-18.12M	281M	-1.09B
Long-Term Debt Issued, Total	-	-	648M	-	-
Total Debt Issued	-	-	648M	-	-
Long-Term Debt Repaid, Total	-8.69M	-29.22M	-14.72M	-450M	-543M
Total Debt Repaid	-8.69M	-29.22M	-14.72M	-450M	-543M
Issuance of Common Stock	698M	833M	775M	1.08B	1.56B
Repurchase of Common Stock	-	-	-28.59M	-	-41.6M
Other Financing Activities, Total	-14.44M	-42.71M	-46.9M	-47.46M	-71.91M
Cash from Financing	674M	761M	1.33B	587M	907M
Foreign Exchange Rate Adjustments	7.07M	3.74M	66.22M	13.68M	-7.24M
Net Change in Cash	220M	-121M	169M	-59.87M	-620M
Supplemental Items
Cash Interest Paid	3.2M	2.9M	3.3M	34.41M	25.25M
Cash Income Tax Paid (Refund)	-93K	-	41.63M	-9.28M	-11.3M
Levered Free Cash Flow	-318M	-434M	-741M	-382M	-229M
Unlevered Free Cash Flow	-316M	-432M	-738M	-347M	-214M
Change In Net Working Capital	-46.96M	-38.17M	153M	-16.29M	-78.94M
Net Debt Issued / Repaid	-8.69M	-29.22M	633M	-450M	-543M

Fiscal Period: December	2019	2020	2021	2022	2023
Profitability
Return on Assets	-25.98	-30.08	-34.28	-28.21	-19.93
Return on Total Capital	-30.06	-37.62	-42.7	-33.31	-22.99
Return On Equity %	-48.46	-68.51	-94.4	-110.75	-58.43
Return on Common Equity	-48.46	-68.51	-94.4	-110.75	-58.43
Margin Analysis
Gross Profit Margin %	99	74.37	59.39	100	-100.74
SG&A Margin	164.23	132.51	217.47	259.18	62.99
EBITDA Margin %	-1.41K	-224.3	-350.07	-698.78	-161.83
EBITA Margin %	-1.42K	-227.01	-356.27	-782.86	-163.73
EBIT Margin %	-1.42K	-228.95	-358.96	-782.86	-163.73
Income From Continuing Operations Margin %	-1.38K	-239.65	-348.01	-928.6	-205.3
Net Income Margin %	-1.38K	-239.65	-348.01	-1.16K	-205.3
Net Avail. For Common Margin %	-1.38K	-239.65	-348.01	-928.6	-205.3
Normalized Net Income Margin	-876.3	-151.25	-217.56	-498.09	-100.91
Levered Free Cash Flow Margin	-768.33	-122.79	-253.28	-367.48	-66.8
Unlevered Free Cash Flow Margin	-763.49	-122.27	-252.4	-334.03	-62.37
Asset Turnover
Asset Turnover	0.03	0.21	0.15	0.06	0.19
Fixed Assets Turnover	0.59	2.09	1.35	0.54	2.17
Receivables Turnover (Average Receivables)	20.54	14.96	4.9	0.77	2.88
Inventory Turnover (Average Inventory)	-	-	1.3	-	149.25
Short Term Liquidity
Current Ratio	7.31	4	5.15	6.73	6.25
Quick Ratio	7.16	3.71	4.6	6.73	6.23
Operating Cash Flow to Current Liabilities	-2.1	-1.94	-3.63	-4.82	-1.5
Days Sales Outstanding (Average Receivables)	17.77	24.47	74.55	472.24	126.7
Days Outstanding Inventory (Average Inventory)	-	-	281.82	-	2.45
Average Days Payable Outstanding	39.66K	-	143	-	71.55
Cash Conversion Cycle (Average Days)	-	-	213.37	-	57.6
Long Term Solvency
Total Debt/Equity	6.9	10.58	84.87	64.23	7.49
Total Debt / Total Capital	6.46	9.57	45.91	39.11	6.96
LT Debt/Equity	6.28	9.44	83.26	62.43	6.44
Long-Term Debt / Total Capital	5.88	8.54	45.04	38.01	5.99
Total Liabilities / Total Assets